Your browser doesn't support javascript.
loading
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
Skowronski, Danuta M; Zhan, Yuping; Kaweski, Samantha E; Sabaiduc, Suzana; Khalid, Ayisha; Olsha, Romy; Carazo, Sara; Dickinson, James A; Mather, Richard G; Charest, Hugues; Jassem, Agatha N; Levade, Inès; Hasso, Maan; Zelyas, Nathan; Gao, Ruimin; Bastien, Nathalie.
Afiliação
  • Skowronski DM; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Zhan Y; University of British Columbia, Vancouver, Canada.
  • Kaweski SE; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Sabaiduc S; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Khalid A; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Olsha R; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Carazo S; Public Health Ontario, Toronto, Canada.
  • Dickinson JA; Institut National de Santé Publique du Québec, Québec, Canada.
  • Mather RG; University of Calgary, Calgary, Canada.
  • Charest H; Public Health Ontario, Toronto, Canada.
  • Jassem AN; Queen's University, Kingston, Canada.
  • Levade I; Institut National de Santé Publique du Québec, Québec, Canada.
  • Hasso M; British Columbia Centre for Disease Control, Vancouver, Canada.
  • Zelyas N; Institut National de Santé Publique du Québec, Québec, Canada.
  • Gao R; Public Health Ontario, Toronto, Canada.
  • Bastien N; Public Health Laboratory, Alberta Precision Laboratories, Edmonton, Canada.
Euro Surveill ; 29(7)2024 Feb.
Article em En | MEDLINE | ID: mdl-38362622
ABSTRACT
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI 33-71) than clade 5a.2a (67%; 95% CI 48-80), and lowest against influenza A(H3N2) (40%; 95% CI 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI 28-85).
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article